Clovis Oncology Valuation

CLVSDelisted Stock  USD 0.09  0.02  24.00%   
Clovis Oncology seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Clovis Oncology from analyzing the firm fundamentals such as Shares Outstanding of 144.96 M, return on asset of -0.3, and Operating Margin of (1.55) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
0.09
Please note that Clovis Oncology's price fluctuation is very steady at this time. Calculation of the real value of Clovis Oncology is based on 3 months time horizon. Increasing Clovis Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Clovis Oncology is useful when determining the fair value of the Clovis stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Clovis Oncology. Since Clovis Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Clovis Stock. However, Clovis Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.093 Real  0.0884 Hype  0.09 Naive  0.13
The real value of Clovis Stock, also known as its intrinsic value, is the underlying worth of Clovis Oncology Company, which is reflected in its stock price. It is based on Clovis Oncology's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Clovis Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Clovis Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
0.09
Real Value
0.10
Upside
Estimating the potential upside or downside of Clovis Oncology helps investors to forecast how Clovis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Clovis Oncology more accurately as focusing exclusively on Clovis Oncology's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.090.090.09
Details
Hype
Prediction
LowEstimatedHigh
0.090.090.10
Details
Naive
Forecast
LowNext ValueHigh
0.130.130.13
Details

Clovis Oncology Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Clovis Oncology's current stock value. Our valuation model uses many indicators to compare Clovis Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clovis Oncology competition to find correlations between indicators driving Clovis Oncology's intrinsic value. More Info.
Clovis Oncology is number one stock in beta category among related companies. It is number one stock in price to sales category among related companies fabricating about  0.49  of Price To Sales per Beta. The ratio of Beta to Price To Sales for Clovis Oncology is roughly  2.06 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Clovis Oncology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Clovis Oncology's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Clovis Oncology's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Clovis Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Clovis Oncology and how it compares across the competition.

About Clovis Oncology Valuation

The delisted stock valuation mechanism determines the current worth of Clovis Oncology on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Clovis Oncology. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Clovis Oncology based exclusively on its fundamental and basic technical indicators. By analyzing Clovis Oncology's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Clovis Oncology's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Clovis Oncology. We calculate exposure to Clovis Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Clovis Oncology's related companies.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 413 people.

8 Steps to conduct Clovis Oncology's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Clovis Oncology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Clovis Oncology's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Clovis Oncology's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Clovis Oncology's revenue streams: Identify Clovis Oncology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Clovis Oncology's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Clovis Oncology's growth potential: Evaluate Clovis Oncology's management, business model, and growth potential.
  • Determine Clovis Oncology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Clovis Oncology's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Clovis Oncology Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Clovis Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding121.2 M
Retained Earnings-2.9 B
Retained Earnings Total Equity-2.9 B
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Consideration for investing in Clovis Stock

If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format